A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

From Pfizer's oncology franchise, I was pleased with the strong sales of Lorbrena, Padcev, Braftovi/Mektovi, and Elrexfio, which helped offset the weak performance of Adcetris and Tukysa.

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

The following are the top rated Health Care stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies ...

A combination of BRAF and MEK inhibitors plus immunotherapy improved progression-free but not overall survival, compared to dual immune checkpoint blockade.

In 2018, it approved Array’s novel–novel pairing of the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) for unresectable or metastatic melanoma with BRAF ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...